Drug intelligence / Profile preview

VRC-ZKADNA090-00-VP

Development stage: Phase 2
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VRC-ZKADNA090-00-VP is a DNA vaccine developed by the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID) for the prevention of Zika virus infection. The vaccine consists of a single closed-circular DNA plasmid (VRC 5283) encoding the wild-type precursor membrane (prM) and envelope (E) proteins from the H/PF/2013 strain of Zika virus. It is designed to induce both cellular and humoral immune responses, leading to production of neutralizing antibodies against Zika virus. Clinical studies have demonstrated that this vaccine elicits strong immunogenicity, with robust neutralizing antibody titers in animal models and humans, as well as protective effects against ZIKV-induced tissue damage in preclinical studies[5][6][9]. The vaccine is administered intramuscularly using a needle-free injection device[3][7].

Other names: Zika virus wildtype DNA vaccineZika virus DNA vaccineVRC 705 vaccineVRC705 vaccineVRC-705 vaccine

Beyond the preview

Go deeper on VRC-ZKADNA090-00-VP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRC-ZKADNA090-00-VP.

Explore the full profile